265 related articles for article (PubMed ID: 35311155)
41. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC).
Albinger-Hegyi A; Stoeckli SJ; Schmid S; Storz M; Iotzova G; Probst-Hensch NM; Rehrauer H; Tinguely M; Moch H; Hegyi I
Int J Cancer; 2010 Jun; 126(11):2653-62. PubMed ID: 19816945
[TBL] [Abstract][Full Text] [Related]
42. Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in rectal cancer patients.
Liu N; Cox TR; Cui W; Adell G; Holmlund B; Ping J; Jarlsfelt I; Erler JT; Sun XF
Oncotarget; 2017 Sep; 8(36):60015-60024. PubMed ID: 28947950
[TBL] [Abstract][Full Text] [Related]
43.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
44. Expression of Lysyl Oxidase Predictive of Distant Metastasis of Laryngeal Cancer.
Lee YS; Park Y; Kwon M; Roh JL; Choi SH; Nam SY; Kim SY
Otolaryngol Head Neck Surg; 2017 Mar; 156(3):489-497. PubMed ID: 28116994
[TBL] [Abstract][Full Text] [Related]
45. Prognostic alternative splicing signature reveals the landscape of immune infiltration in Pancreatic Cancer.
Wang L; Bi J; Li X; Wei M; He M; Zhao L
J Cancer; 2020; 11(22):6530-6544. PubMed ID: 33046974
[No Abstract] [Full Text] [Related]
46. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer.
Jiang WG; Douglas-Jones AG; Mansel RE
Prostaglandins Leukot Essent Fatty Acids; 2006 Feb; 74(2):125-34. PubMed ID: 16364620
[TBL] [Abstract][Full Text] [Related]
47. A tissue-specific variant of the human lysyl oxidase-like protein 3 (LOXL3) functions as an amine oxidase with substrate specificity.
Lee JE; Kim Y
J Biol Chem; 2006 Dec; 281(49):37282-90. PubMed ID: 17018530
[TBL] [Abstract][Full Text] [Related]
48. Over-expression of lysyl oxidase is associated with poor prognosis and response to therapy of patients with lower grade gliomas.
Huang SP; Chiou J; Jan YH; Lai TC; Yu YL; Hsiao M; Lin YF
Biochem Biophys Res Commun; 2018 Jun; 501(3):619-627. PubMed ID: 29729273
[TBL] [Abstract][Full Text] [Related]
49. Interferon regulatory factor family influences tumor immunity and prognosis of patients with colorectal cancer.
Chen YJ; Luo SN; Dong L; Liu TT; Shen XZ; Zhang NP; Liang L
J Transl Med; 2021 Sep; 19(1):379. PubMed ID: 34488791
[TBL] [Abstract][Full Text] [Related]
50. Lysyl oxidase induces epithelial-mesenchymal transition and predicts intrahepatic metastasis of hepatocellular carcinoma.
Umezaki N; Nakagawa S; Yamashita YI; Kitano Y; Arima K; Miyata T; Hiyoshi Y; Okabe H; Nitta H; Hayashi H; Imai K; Chikamoto A; Baba H
Cancer Sci; 2019 Jun; 110(6):2033-2043. PubMed ID: 30919528
[TBL] [Abstract][Full Text] [Related]
51. AMICA1 is a diagnostic and prognostic biomarker and induces immune cells infiltration by activating cGAS-STING signaling in lung adenocarcinoma.
Feng Z; Zhang Y; He M; Han Y; Cai C; Liu S; Liu P; Chen Y; Shen H; Zeng S
Cancer Cell Int; 2022 Mar; 22(1):111. PubMed ID: 35248033
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
Hajdú I; Kardos J; Major B; Fabó G; Lőrincz Z; Cseh S; Dormán G
Bioorg Med Chem Lett; 2018 Oct; 28(18):3113-3118. PubMed ID: 30098867
[TBL] [Abstract][Full Text] [Related]
53. LOX expression in primary nasopharyngeal carcinoma: correlation with prognostic parameters and outcome.
Hua YJ; Wang HY; Tang LQ; Chen QY; Shao JY; Mai HQ
Oncotarget; 2016 Feb; 7(7):8200-7. PubMed ID: 26882568
[TBL] [Abstract][Full Text] [Related]
54. Lysyl oxidase: from basic science to future cancer treatment.
Nishioka T; Eustace A; West C
Cell Struct Funct; 2012; 37(1):75-80. PubMed ID: 22453058
[TBL] [Abstract][Full Text] [Related]
55. LOXL2 Inhibitors and Breast Cancer Progression.
Ferreira S; Saraiva N; Rijo P; Fernandes AS
Antioxidants (Basel); 2021 Feb; 10(2):. PubMed ID: 33669630
[TBL] [Abstract][Full Text] [Related]
56. Lysyl oxidase: A colorectal cancer biomarker of lung and hepatic metastasis.
Liu Y; Wang G; Liang Z; Mei Z; Wu T; Cui A; Liu C; Cui L
Thorac Cancer; 2018 Jul; 9(7):785-793. PubMed ID: 29766649
[TBL] [Abstract][Full Text] [Related]
57. LOX and ACSL5 as potential relapse markers for pancreatic cancer patients.
Ma W; Li T; Wu S; Li J; Wang X; Li H
Cancer Biol Ther; 2019; 20(6):787-798. PubMed ID: 30712446
[TBL] [Abstract][Full Text] [Related]
58. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.
Liu J; Ping W; Zu Y; Sun W
Int J Clin Exp Pathol; 2014; 7(9):6040-7. PubMed ID: 25337249
[TBL] [Abstract][Full Text] [Related]
59. Lysyl oxidase, extracellular matrix remodeling and cancer metastasis.
Xiao Q; Ge G
Cancer Microenviron; 2012 Dec; 5(3):261-73. PubMed ID: 22528876
[TBL] [Abstract][Full Text] [Related]
60. Serum LOX-1 is a novel prognostic biomarker of colorectal cancer.
Nakashima-Nakasuga C; Hazama S; Suzuki N; Nakagami Y; Xu M; Yoshida S; Tomochika S; Fujiwara N; Matsukuma S; Matsui H; Tokumitsu Y; Kanekiyo S; Shindo Y; Maeda N; Tsunedomi R; Iida M; Takeda S; Yoshino S; Ueno T; Hamamoto Y; Ogihara H; Hoshii Y; Nagano H
Int J Clin Oncol; 2020 Jul; 25(7):1308-1317. PubMed ID: 32277394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
